Key result
CAC scanning guides statin therapy in intermediate-risk patients, where zero scores indicate <5% 10-year risk.
Why the study?
Does coronary artery calcium scanning improve risk stratification for statin therapy in intermediate-risk patients?
Does coronary artery calcium scanning improve risk stratification for statin therapy in intermediate-risk patients?
Answers are grounded in this paper and cite their sources.
Coronary artery calcium scoring provides a strong evidence-based approach to refine risk assessment and guide statin therapy decisions in primary prevention for intermediate-risk patients.
In 2018, cardiovascular society cholesterol guidelines recommended the use of coronary artery calcium to guide statin therapy in patients 40-79 years of age who are at intermediate risk by multiple risk factor equations (ie, estimated 10-year risk for atherosclerotic disease of 7.5%-19.9% but in whom statin benefit is uncertain). Many such patients have no coronary calcium and remain at <5% risk over the next decade; hence, statin therapy can be delayed until a repeat calcium scan is conducted. Exceptions include patients with severe hypercholesterolemia, diabetes, and a strong family history of atherosclerotic disease. If coronary calcium equals 1-99 Agatston units, the 10-year risk is borderline (5% to <7.5%) and statin therapy is optional pending a repeat scan. If coronary calcium equals 100-299 Agatston units, the patient is clearly statin eligible (7.5% to <20% 10-year risk). And finally, if coronary calcium is ≥300 Agatston units, a patient is at high risk and is a candidate for high-intensity statins. Risk factor analysis combined judiciously with coronary calcium scanning offers the strongest evidence-based approach to use of statins in primary prevention.
No takes yet. Share an insight, caveat, or question.
Grundy et al. (2021) conducted a review in Atherosclerotic cardiovascular disease. Coronary artery calcium scanning was evaluated. Coronary artery calcium scanning guides statin therapy in intermediate-risk patients, where a score of 0 indicates <5% 10-year risk and a score ≥100 indicates statin eligibility.
Synapse has enriched 10 related papers. Consider them for comparative context: